Invest-in-America
4 months ago
XRTX: Who would believe it???!!! The Wall Street WINNER OF THE DAY, behind THAT kind of typical, theoretical, academic, journal, PURE-FLUFF "news"!!!! (What a MINDLESS, ignorant, Planet, we all live upon!!! HOW ignorant IS this stupid Planet??? Well, the fact that "GERIATRICS" departments are found in ALL "hospitals" on this useless Planet says it all!!! Mankind can NOT even stop the Human Aging Process by one fucking SECOND!!!)
AveragePenny
11 months ago
$XRTX XORTX Announces $2 Million Public Offering
https://www.globenewswire.com/news-release/2024/01/15/2809090/0/en/XORTX-Announces-2-Million-Public-Offering.html
CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the filing of a prospectus supplement on a non-brokered offering of up to 666,667 common share units (“Common Share Units”), with each Common Share Unit consisting of one common share, no par value, and one warrant (“Warrant”) to purchase one common share at $4.50 per common share for a period of two years for aggregate gross proceeds of up to $2 million, prior to deducting offering expenses (the “Offering”). The common shares and Warrants contained in the Common Share Units are immediately separable upon issuance. The Warrants have an initial exercise price of $4.50 per share, will be immediately exercisable, and may be exercised for two years from the date of issuance, provided, however that, if, the common shares on the TSX Venture Exchange (“TSXV”) trade at greater than $6.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30th business day following the date of such notice.
The Offering is expected to close on or about January 25, 2024, subject to satisfaction of customary closing conditions.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The Company also announces that it has entered into a consulting agreement with Plutus Bridge Capital Inc. (“Plutus”) to provide social media marketing and related services in accordance with TSXV policies (the “Consulting Agreement”). Plutus is an independently owned public relations and capital markets consultancy firm based in Vancouver, British Columbia. In connection with the engagement, the Company has advanced US$25,000 plus applicable taxes to cover the start-up costs associated with the public relations campaign and related services. A further budget will be required to expand the program at the discretion and approval of the Company. The engagement is for an initial term of six months until June 30, 2024. The Consulting Agreement can be extended by mutual consent and can be terminated by either party on 30 days written notice. XORTX and Plutus are unrelated and unaffiliated entities. Plutus has informed the Company that it currently has no present, direct or indirect, interest in XORTX or any securities of XORTX.
AveragePenny
12 months ago
$XRTX XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
https://www.globenewswire.com/news-release/2024/01/03/2803143/0/en/XORTX-Submits-a-New-Patent-for-the-Treatment-of-Chronic-Kidney-Disease.html
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.
The positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported in Q1 2023 (the “Study”) characterized the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLO™. Results from the Study showed that XORLO™ was well tolerated by the 88 subjects who received the drug. There were no safety concerns during the testing of drug across the various dosing regimens used. Overall results were positive and showed: i) a substantial increase in the bioavailability of oxypurinol with the XORLO™ formulation platform; (ii) a substantially increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values. In simple terms, substantially increased early oral absorption of XORLO™, and increased circulating concentrations of oxypurinol necessary to inhibit production of uric acid across the desired therapeutic range and thereby slow down the advancements of CKD. Each of these results will provide key data to facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease due to ADPKD as well as other causes of CKD.
Dr. Allen Davidoff, CEO of XORTX, commented, “The Bridging Pharmacokinetic Study reported this year provided a wealth of clinical data regarding the potential substantive benefit of the novel formulations of the xanthine inhibitor class of drugs. Analysis of this data set, the use of in silico based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how to address the challenges of dosing in progressing kidney disease. This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future. Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.”
aries4747
1 year ago
$XRTX: XORTX Clarifies Timing for Share Consolidation
Nov. 10, 2023 7:00 AM ETXORTX Therapeutics Inc. (XRTX), XRTX:CA
CALGARY, Alberta, Nov. 10, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XRTX) ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of November 8th, the consolidation of the Company’s common shares on the basis of one post-consolidation Share for every nine pre-consolidation Shares (the “Consolidation”), will now be undertaken today with the shares expected to begin trading on a post-consolidation basis on the TSX Venture Exchange (“TSXV”) and the Nasdaq Capital Market (“Nasdaq”) when markets open on or about Tuesday, November 14, 2023.
The Shares will continue to trade on the TSXV and Nasdaq under the symbol “XRTX” on a post-Consolidation basis, under a new CUSIP number – 98420Q306.
The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to nine pre-consolidation Shares for every one post-consolidation Share at the special meeting of shareholders of the Company held on October 27, 2023. As a result of the Consolidation, the number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854, subject to adjustment for rounding. No fractional shares will be issued in connection with the Consolidation. If a holder of Shares would otherwise be entitled to a fraction of a share, then the number of post-Consolidation Shares issuable to such shareholder shall be rounded down to the next lower whole number. No cash consideration will be paid in respect of fractional shares. The exercise or conversion price and/or the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
Shareholders of record as of the Effective Date will receive a letter of transmittal from TSX Trust Company, the transfer agent for the Shares, providing instructions for the exchange of their Shares as soon as practicable following the Effective Date. Until surrendered, each share certificate representing pre-Consolidation Shares will represent the number of whole post-Consolidation shares to which the holder is entitled as a result of the Consolidation.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Respiratory Viral infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients with kidney disease. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
Allen Davidoff, CEO
adavidoff@xortx.com or +1 403 455 7727
Nick Rigopulos, Director of Communications
nick@alpineequityadv.com or +1 617 901 0785
Media Inquiries, OIipriya Das, PhD, MSc
olipriya.das@russopartnersllc.com or +1 409 365 3641
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
https://www.globenewswire.com/newsroom/ti?nf=ODk3NzA4NiM1OTIyMzE3IzIwOTcyNzk=
crudeoil24
1 year ago
Shares of XRTX are trending on Yahoo Finance and moving on remarkably heavy trading volume Friday, despite a lack of company-specific news.
According to data from Benzinga Pro, more than 45 million shares have already been traded in the session, compared to the stock's 100-day average of just over 200 thousand shares.
Xortx Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection.
Related News: What's Going On With Bitcoin Mining Stocks Marathon Digital And Riot Platforms?
XRTX Price Action: According to Benzinga Pro, Xortx Therapeutics shares are up 52% at 53 cents at the time of publication.
Level up your trading with our powerful tools and real-time insights all in one place.
glenn1919
2 months ago
bigfart
4 months ago
Monksdream
9 months ago
SantaZar
1 year ago
Golden Cross
1 year ago
Zorro
1 year ago
willlbone
1 year ago
TheFinalCD
2 years ago
hawkshaw812
2 years ago
INFINITI
2 years ago
Hot Features
Premium
